Overview
Bioxodes develops an innovative pipeline in thrombo-inflammation with BIOX-101 as its lead candidate. The drug has a unique mechanism of action targeting neutrophils and coagulation factors (FXIIa, FXIa) for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.
Key people
In the news
- Chief Executive Officer Marc Dechamps will join a panel discussion at COG Europe 2026 in Amsterdam to discuss one of the key challenges facing biotech companies today: securing funding to advance clinical development. The session,"𝐒𝐡𝐨𝐰 𝐌𝐞 𝐓𝐡𝐞 𝐌𝐨𝐧𝐞𝐲: 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐚𝐧𝐝 𝐏𝐨𝐬𝐢𝐭𝐢𝐨𝐧𝐢𝐧𝐠 𝐘𝐨𝐮𝐫 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬", will explore how biotech companies can successfully navigate the transition from discovery to clinical development, attract investment, and build compelling value propositions for
- Our Chief Executive Officer Marc Dechamps will join a panel discussion at the 1st European Healthcare Impact Summit, organized by Sachs Associates in Basel. Stroke remains one of the leading causes of death and disability worldwide, yet treatment options remain limited for patients suffering from intracerebral hemorrhage (ICH), the deadliest form of stroke and a condition for which no approved therapy exists. Marc will participate in the panel “𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫 𝐢𝐧 𝐒𝐭𝐫𝐨𝐤𝐞 𝐂𝐚𝐫𝐞: 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬,
- We are pleased to welcome our new Head of Finance Tomas Comblain to the Bioxodes team! It is always encouraging to see talent transition from the academic environment into the biotech ecosystem, and even more so when that journey comes full circle. After completing the Solvay Advanced Master in Biotech & Medtech Ventures, where he was introduced to the industry by members of our team, he has now joined Bioxodes to support the next phase of our development. As we advance BIOX‑101 and prepare for upcoming clinical milestones,
Something wrong or missing? Send an update. Fixed within 24 hours.